MacroGenics | MGNX - Cash And Equivalent

Stock Price
4.35
Daily Change
0.10 2.35%
Monthly
25.00%
Yearly
173.58%
Q2 Forecast
4.16

MacroGenics reported $66.52M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Geron USD 68.9M 10.54M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Xencor USD 14.17M 39.9M Mar/2026